GeoVax to Announce Q2 2025 Financial Results and Corporate Update

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, announced it will release its second quarter 2025 financial results on July 28, 2025, after the U.S. markets close. The announcement will be followed by a conference call and webcast at 4:30 p.m. ET, where management will discuss the financial results and provide a corporate update. This event is crucial for investors and stakeholders interested in GeoVax's advancements in developing vaccines and immunotherapies for infectious diseases and cancer.

Interested parties can access the live conference call by registering here, with the webcast available on GeoVax's website under 'Events and Presentations' in the Investor Relations section. Telephone participants are advised to register in advance to receive dial-in details. The webcast will be archived on the company's website for at least 90 days post-event, ensuring wide accessibility.

GeoVax's lead clinical programs include GEO-CM04S1, a next-generation COVID-19 vaccine in Phase 2 trials, and Gedeptin®, an oncolytic solid tumor gene-directed therapy. The company is also advancing a vaccine for Mpox and smallpox, with plans to proceed directly to Phase 3 trials. These developments underscore GeoVax's commitment to addressing unmet medical needs through innovative vaccine and immunotherapy solutions.